CAP

AIIB Unveils Climate Action Plan, Reinforces Commitment to Tackle Climate Change

Retrieved on: 
Monday, September 25, 2023

SHARM EL-SHEIKH, Egypt, Sept. 25, 2023 /PRNewswire/ -- The Asian Infrastructure Investment Bank (AIIB) has launched its inaugural Climate Action Plan (CAP), a milestone in the Bank's ongoing commitment to combatting climate change.

Key Points: 
  • SHARM EL-SHEIKH, Egypt, Sept. 25, 2023 /PRNewswire/ -- The Asian Infrastructure Investment Bank (AIIB) has launched its inaugural Climate Action Plan (CAP), a milestone in the Bank's ongoing commitment to combatting climate change.
  • It is a dynamic framework that can evolve to stay pertinent and impactful as the ramifications of climate change intensify.
  • "The Climate Action Plan demonstrates AIIB's ambition to mobilize our capital, capacity and convening power to help our members in their efforts to address climate change," said AIIB President and Chair of the Board Jin Liqun.
  • To access AIIB's Climate Action Plan and learn more about the Bank's commitment to climate action, please visit here .

AIIB Unveils Climate Action Plan, Reinforces Commitment to Tackle Climate Change

Retrieved on: 
Monday, September 25, 2023

SHARM EL-SHEIKH, Egypt, Sept. 25, 2023 /PRNewswire/ -- The Asian Infrastructure Investment Bank (AIIB) has launched its inaugural Climate Action Plan (CAP), a milestone in the Bank's ongoing commitment to combatting climate change.

Key Points: 
  • SHARM EL-SHEIKH, Egypt, Sept. 25, 2023 /PRNewswire/ -- The Asian Infrastructure Investment Bank (AIIB) has launched its inaugural Climate Action Plan (CAP), a milestone in the Bank's ongoing commitment to combatting climate change.
  • It is a dynamic framework that can evolve to stay pertinent and impactful as the ramifications of climate change intensify.
  • "The Climate Action Plan demonstrates AIIB's ambition to mobilize our capital, capacity and convening power to help our members in their efforts to address climate change," said AIIB President and Chair of the Board Jin Liqun.
  • To access AIIB's Climate Action Plan and learn more about the Bank's commitment to climate action, please visit here .

Vestaron and CAP Join Forces to Revolutionize Portuguese Agriculture with Sustainable Inputs

Retrieved on: 
Tuesday, September 19, 2023

The collaboration marks a significant step forward in sustainable agriculture and promises to enhance both productivity and environmental stewardship within the Portuguese farming community.

Key Points: 
  • The collaboration marks a significant step forward in sustainable agriculture and promises to enhance both productivity and environmental stewardship within the Portuguese farming community.
  • Vestaron and CAP will work hand in hand to provide Portuguese farmers with access to state-of-the-art agricultural inputs that have the potential to transform their operations.
  • "We are excited to partner with CAP to bring our innovative biopesticide solutions to Portuguese growers," said Anna Rath, CEO of Vestaron.
  • Luis Mira, CAP Secretary General, expressed enthusiasm for the collaboration: "CAP is dedicated to promoting agricultural advancements that prioritize long-term sustainability.

USMI to Debut the Canady Robotic AI Surgical System at the First Global Surgical Oncology Summit Jerusalem, Israel January 2024

Retrieved on: 
Friday, September 22, 2023

The Canady Robotic AI Surgical System is the world’s first AI robotic system that delivers cold atmospheric plasma (CAP) which is a three-dimensional non-contact bioelectric pulse electromagnetic field.

Key Points: 
  • The Canady Robotic AI Surgical System is the world’s first AI robotic system that delivers cold atmospheric plasma (CAP) which is a three-dimensional non-contact bioelectric pulse electromagnetic field.
  • The Canady Robotic AI Surgical System will be displayed at the First Global Surgical Oncology Summit in Jerusalem, Israel (January 30 to February 2, 2024).
  • View the full release here: https://www.businesswire.com/news/home/20230922283953/en/
    Canady Robotic AI Surgical System (Photo: Business Wire)
    The Canady Robotic AI Surgical System’s key components are a Motorized Positioning Arm, Speech Recognition Canady Electrosurgical Generator known as ORLI™, Controller for CAP Devices, Robotic Assisted End Effectors which can be used in Open, Laparoscopic, Thoracoscopic, Endoscopic and Mini-invasive surgical procedures.
  • Taisen Zhuang, PhD, Chief Technology Officer stated, “The Canady Robotic AI Surgical System sets a new precedent for Robotic Cancer Surgery by combining AI Technology and CAP.

bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services

Retrieved on: 
Tuesday, September 19, 2023

bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, announces the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, a clinical laboratory accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988.

Key Points: 
  • bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, announces the acquisition of the laboratory assets of Village Oaks Pathology Services, P.A., d/b/a Precision Pathology Services, a clinical laboratory accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988.
  • The laboratory assets are being acquired by a new wholly owned subsidiary of bioAffinity Technologies, Precision Pathology Laboratory Services, LLC (PPLS).
  • Precision Pathology provides pathology services to physicians practicing in a variety of outpatient settings and has offered bioAffinity Technologies’ CyPath® Lung as a laboratory developed test for the detection of early-stage lung cancer.
  • In addition to CyPath® Lung, Precision Pathology offers a range of laboratory services including respiratory testing for SARS-CoV-2 and influenza, anatomic pathology, morphological stains, histological services, DNA extractions, STI testing, and women’s and men’s health testing.

Now Available - Gestalt Announces AI for Mitotic Counting

Retrieved on: 
Tuesday, September 19, 2023

SPOKANE, Wash., Sept. 19, 2023 /PRNewswire/ -- Gestalt Diagnostics is proud to announce our latest release – an AI algorithm for use on one of the broadest trained environments for commercial or research use. The Mitotic Counting algorithm was trained on over 100,000 individual mitosis and across seven scanner models. The algorithm boasts an F1-Score of 0.74, which is tantamount to the best state-of-the-art methods.

Key Points: 
  • The Mitotic Counting algorithm was trained on over 100,000 individual mitosis and across seven scanner models.
  • This algorithm is available today in the Gestalt AI Studio™ and for use on - Cutaneous mast cell tumor, breast cancer, lymphoma, lung cancer, melanoma, neuroendocrine, colon cancer, and bladder carcinoma.
  • Lisa-Jean Clifford, Gestalt COO & Chief Strategy Officer, asks: "What does this mean for our customers?
  • "We are extremely proud of the comprehensive approach we take to AI development as an organization.

Clinical whole genome sequencing test developed at The Jackson Laboratory

Retrieved on: 
Friday, September 15, 2023

A decade ago, sequencing centers began offering clinical whole exome sequencing, but these only cover the portion of the genome that codes for proteins – approximately 1.5 percent of the entire genome.

Key Points: 
  • A decade ago, sequencing centers began offering clinical whole exome sequencing, but these only cover the portion of the genome that codes for proteins – approximately 1.5 percent of the entire genome.
  • To improve the diagnostic power of sequencing and identify the genetic basis of disease, the Advanced Precision Medicine Laboratory (APML) at The Jackson Laboratory for Genomic Medicine (JAX) in Farmington, Connecticut, is offering a fully validated, clinical whole genome sequencing test.
  • The APML is CLIA certified and CAP accredited and the JAX Genome test is the only clinical whole genome sequencing test currently offered in Connecticut.
  • The JAX Genome test includes DNA extraction from whole blood, sequencing of the genome, and variant analysis and interpretation.

New Study Shows Threat to Philippine Consumers From Piracy Sites Remains Greater Than Ever

Retrieved on: 
Friday, September 15, 2023

The report found that Filipino consumers visiting pirate streaming sites are 21.66 times more likely to be infected with malware compared to mainstream sites (with a verifiable detection rate of 10%(1)).

Key Points: 
  • The report found that Filipino consumers visiting pirate streaming sites are 21.66 times more likely to be infected with malware compared to mainstream sites (with a verifiable detection rate of 10%(1)).
  • When visiting pirate torrent sites, Filipino consumers are 16.66 times more likely than mainstream sites to be infected with malware (with a verifiable infection rate of 18%).
  • Matt Cheetham, General Manager of CAP, noted, "Evidence continues to mount that far from being a victimless crime, piracy can victimize consumers."
  • (1) In addition to the relative risk calculations, researchers verified that 10% of visits to pirate streaming sites resulted in malware infection.

EQS-News: Biotest AG: Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin

Retrieved on: 
Saturday, September 16, 2023

Biotest announced today that the first patient with sCAP has been treated in the phase III ESsCAPE trial in an intensive care unit.

Key Points: 
  • Biotest announced today that the first patient with sCAP has been treated in the phase III ESsCAPE trial in an intensive care unit.
  • This multinational phase III clinical trial is expected to enrol approximately 590 adult patients with severe Community Acquired Pneumonia (sCAP).
  • In the CIGMA trial a subgroup of patients with evidence of severe inflammation showed an encouraging reduction in the mortality rate when treated with trimodulin.
  • In addition to clinical development for sCAP, trimodulin is also currently in development for the treatment of COVID-19.

NEC X Announces Elev X! - Program to Launch Technology Startups and Accelerate Business Growth

Retrieved on: 
Thursday, September 14, 2023

venture studio program is designed to launch new technology startups and accelerate the growth of early-stage startups.

Key Points: 
  • venture studio program is designed to launch new technology startups and accelerate the growth of early-stage startups.
  • During these efforts, NEC X collaborated with ideation-phase entrepreneurs and discovered many pre-seed and seed-stage startups in need of specific technology and expertise.
  • Elev X!
  • The event is supported by the Massachusetts Institute of Technology (MIT) Industrial Liaison Program (ILP), which is also a collaborator with startups in Elev X!.